1177:HKEXSino Biopharmaceutical Limited Analysis

The stock trades at 17,740 KRW, well above its DCF‑derived fair value of roughly 3,550 KRW, indicating a substantial overvaluation. Price remains below the 20‑day SMA (19,555) and the 50‑day SMA (19,270), a bearish signal reinforced by a negative MACD histogram and a “bearish” MACD signal line. RSI sits at 42, suggesting neither extreme oversold nor overbought conditions. Volume is increasing, but the 30‑day volatility of 72% highlights a highly erratic price environment. The beta of 1.04 points to market‑aligned risk, while the Fear & Greed Index at “Extreme Greed” reflects overly optimistic sentiment.
Fundamentally, the company posted a 35.7% revenue contraction and negative operating (‑36%) and profit margins (‑98%), with an ROE of –84%, underscoring severe profitability challenges. Its balance sheet shows a debt‑to‑equity ratio of 36.8 and total debt exceeding 20 billion KRW, raising concerns about financial leverage. Free cash flow is deeply negative (‑12.7 billion KRW) despite positive operating cash flow, indicating cash‑burn pressure. No dividend is paid, so dividend sustainability is moot. Geographic exposure across Korea, China and the United States adds medium‑level geopolitical and currency risk, while the technology‑hardware sector is inherently cyclical, contributing to a high sector risk rating. Given these pressures, the upside potential appears limited despite the bullish trend label.